Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Tuberculosis

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 62 articles: HTML format Text format

Single Articles

October 2019
1. MARKS GB, Nguyen NV, Nguyen PTB, Nguyen TA, et al
   Community-wide Screening for Tuberculosis in a High-Prevalence Setting.
   N Engl J Med. 2019;381:1347-1357.
   PubMed     Text format     Abstract available
   
   
   September 2019
2. CHAISSON RE, Ramchandani R, Swindells S
   One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
   N Engl J Med. 2019;381:e23.
   PubMed     Text format    
   
   
   
3. STOUT JE, Sterling TR, Horsburgh CR Jr
   One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
   N Engl J Med. 2019;381:e23.
   PubMed     Text format    
   
   
   
4. NUNN AJ, Phillips PPJ
   A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
   N Engl J Med. 2019;381:e22.
   PubMed     Text format    
   
   
   
5. TORNHEIM JA, Udwadia ZF, Gupta A
   A Shorter Regimen for Rifampin-Resistant Tuberculosis.
   N Engl J Med. 2019;381:e22.
   PubMed     Text format    
   
   
   
6. MCCAW ZR, Meng Z, Wei LJ
   A Shorter Regimen for Rifampin-Resistant Tuberculosis.
   N Engl J Med. 2019;381:e22.
   PubMed     Text format    
   
   
   
7. YOELI E, Rathauser J, Bhanot SP, Kimenye MK, et al
   Digital Health Support in Treatment for Tuberculosis.
   N Engl J Med. 2019;381:986-987.
   PubMed     Text format    
   
   
   August 2019
8. LUBKE N, Jensen B, Huttig F, Feldt T, et al
   Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.
   N Engl J Med. 2019;381:887-889.
   PubMed     Text format    
   
   
   July 2019
9. HAVLIR DV, Balzer LB, Charlebois ED, Clark TD, et al
   HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.
   N Engl J Med. 2019;381:219-229.
   PubMed     Text format     Abstract available
   
   
   June 2019
10. KHALILI H, O'Shea A, Robbins GK, Zukerberg LR, et al
    Case 19-2019: A 38-Year-Old Woman with Abdominal Pain and Fever.
    N Engl J Med. 2019;380:2461-2470.
    PubMed     Text format    
    
    
    May 2019
11. DE VOS M, Ley SD, Wiggins KB, Derendinger B, et al
    Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.
    N Engl J Med. 2019;380:2178-2180.
    PubMed     Text format    
    
    
    
12. MEINTJES G, Stek C, Maartens G
    Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS. Reply.
    N Engl J Med. 2019;380:1781.
    PubMed     Text format    
    
    
    
13. JONES MB
    Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS.
    N Engl J Med. 2019;380:1780-1781.
    PubMed     Text format    
    
    
    March 2019
14. SAUNDERS MJ, Evans CA
    Ending Tuberculosis through Prevention.
    N Engl J Med. 2019;380:1073-1074.
    PubMed     Text format    
    
    
    
15. SWINDELLS S, Ramchandani R, Gupta A, Benson CA, et al
    One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    N Engl J Med. 2019;380:1001-1011.
    PubMed     Text format     Abstract available
    
    
    
16. NUNN AJ, Phillips PPJ, Meredith SK, Chiang CY, et al
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMoa1811867.
    PubMed     Text format     Abstract available
    
    
    
17. CHURCHYARD GJ
    A Short Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMe1902904.
    PubMed     Text format    
    
    
    January 2019
18. CHEN ST, Cahalane AM, Ryan ET, Foreman RK, et al
    Case 2-2019: A 36-Year-Old Man with Rash, Abdominal Pain, and Lymphadenopathy.
    N Engl J Med. 2019;380:275-283.
    PubMed     Text format    
    
    
    
19. ALSULTAN A, Ashkin D, Peloquin CA
    Bacterial Factors and Relapse after Tuberculosis Therapy.
    N Engl J Med. 2019;380:197.
    PubMed     Text format    
    
    
    
20. 
    Bacterial Factors and Relapse after Tuberculosis Therapy.
    N Engl J Med. 2019;380:197-198.
    PubMed     Text format    
    
    
    November 2018
21. 
    H4:IC31 Vaccine or BCG Revaccination for Tuberculosis.
    N Engl J Med. 2018;379:1969.
    PubMed     Text format    
    
    
    
22. MEINTJES G, Stek C, Blumenthal L, Thienemann F, et al
    Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
    N Engl J Med. 2018;379:1915-1925.
    PubMed     Text format     Abstract available
    
    
    September 2018
23. RUBIN AK, Burk KS, Staller K, Kunitake H, et al
    Case 30-2018: A 66-Year-Old Woman with Chronic Abdominal Pain.
    N Engl J Med. 2018;379:1263-1272.
    PubMed     Text format    
    
    
    
24. COX H, Mizrahi V
    The Coming of Age of Drug-Susceptibility Testing for Tuberculosis.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMe1811861.
    PubMed     Text format    
    
    
    
25. 
    Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMoa1800474.
    PubMed     Text format     Abstract available
    
    
    
26. BLOOM BR
    New Promise for Vaccines against Tuberculosis.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMe1812483.
    PubMed     Text format    
    
    
    
27. VAN DER MEEREN O, Hatherill M, Nduba V, Wilkinson RJ, et al
    Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1803484.
    PubMed     Text format     Abstract available
    
    
    
28. MANDAL J, Margaretten M
    Tuberculosis of the Finger.
    N Engl J Med. 2018;379:1161.
    PubMed     Text format    
    
    
    
29. OKAMOTO K, Hatakeyama S
    Tuberculous Peritonitis.
    N Engl J Med. 2018;379:e20.
    PubMed     Text format    
    
    
    August 2018
30. COLANGELI R, Jedrey H, Kim S, Connell R, et al
    Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    N Engl J Med. 2018;379:823-833.
    PubMed     Text format     Abstract available
    
    
    
31. RUBIN EJ
    Of MICs and Men.
    N Engl J Med. 2018;379:882-883.
    PubMed     Text format    
    
    
    
32. MENZIES D, Adjobimey M, Ruslami R, Trajman A, et al
    Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
    N Engl J Med. 2018;379:440-453.
    PubMed     Text format     Abstract available
    
    
    
33. DIALLO T, Adjobimey M, Ruslami R, Trajman A, et al
    Safety and Side Effects of Rifampin versus Isoniazid in Children.
    N Engl J Med. 2018;379:454-463.
    PubMed     Text format     Abstract available
    
    
    July 2018
34. NEMES E, Geldenhuys H, Rozot V, Rutkowski KT, et al
    Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    N Engl J Med. 2018;379:138-149.
    PubMed     Text format     Abstract available
    
    
    May 2018
35. YATES TA
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140-1.
    PubMed     Text format    
    
    
    
36. JAIN Y, Laux T, Patil S
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140.
    PubMed     Text format    
    
    
    
37. 
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140-2141.
    PubMed     Text format    
    
    
    
38. FARIA D, Freitas A
    Tuberculous Pericarditis.
    N Engl J Med. 2018;378:e27.
    PubMed     Text format    
    
    
    
39. MCBRIDE JA, Lepak AJ, Dhaliwal G, Saint S, et al
    The Wrong Frame of Mind.
    N Engl J Med. 2018;378:1716-1721.
    PubMed     Text format    
    
    
    March 2018
40. THOMPSON RW, Yu H, Dahl DM, Hurtado RM, et al
    Case 10-2018: An 84-Year-Old Man with Painless Unilateral Testicular Swelling.
    N Engl J Med. 2018;378:1233-1240.
    PubMed     Text format    
    
    
    February 2018
41. BAO Y, Zheng Y
    Drug-Resistant Miliary Tuberculosis in a Child.
    N Engl J Med. 2018;378:e10.
    PubMed     Text format    
    
    
    January 2018
42. FOX GJ, Nhung NV, Sy DN, Hoa NLP, et al
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:221-229.
    PubMed     Text format     Abstract available
    
    
    December 2017
43. GREENE JA, Loscalzo J
    Putting the Patient Back Together - Social Medicine, Network Medicine, and the Limits of Reductionism.
    N Engl J Med. 2017;377:2493-2499.
    PubMed     Text format    
    
    
    
44. MAITRE T, Aubry A, Veziris N
    Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:2403-4.
    PubMed     Text format    
    
    
    
45. 
    Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:2403-2404.
    PubMed     Text format    
    
    
    September 2017
46. BAYER R, Castro KG
    Tuberculosis Elimination in the United States - The Need for Renewed Action.
    N Engl J Med. 2017;377:1109-1111.
    PubMed     Text format    
    
    
    
47. XIE YL, Chakravorty S, Armstrong DT, Hall SL, et al
    Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:1043-1054.
    PubMed     Text format     Abstract available
    
    
    August 2017
48. LETOURNEAU AR, Price MC, Azar MM
    Case 26-2017.
    N Engl J Med. 2017;377:770-778.
    PubMed     Text format    
    
    
    June 2017
49. DAVID WS, Bowley MP, Mehan WA Jr, Shin JH, et al
    Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness.
    N Engl J Med. 2017;376:2471-2481.
    PubMed     Text format    
    
    
    
50. RUBIN EJ
    Reviving a Drug for Tuberculosis?
    N Engl J Med. 2017;376:2292-2294.
    PubMed     Text format    
    
    
    March 2017
51. KORATALA A, Bhatti V
    Incidental Finding of Oleothorax.
    N Engl J Med. 2017;376:e21.
    PubMed     Text format    
    
    
    February 2017
52. GISMONDI RA, de Souza LF
    Empyema Necessitatis.
    N Engl J Med. 2017;376:e13.
    PubMed     Text format    
    
    
    January 2017
53. CASADEVALL A
    Antibodies to Mycobacterium tuberculosis.
    N Engl J Med. 2017;376:283-285.
    PubMed     Text format    
    
    
    
54. SHAH NS, Auld SC, Brust JC, Mathema B, et al
    Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.
    N Engl J Med. 2017;376:243-253.
    PubMed     Text format     Abstract available
    
    
    December 2016
55. BRUST JC, Shah NS, Gandhi NR
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2610.
    PubMed     Text format    
    
    
    
56. 
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609-2611.
    PubMed     Text format    
    
    
    
57. DIACON AH, Van Baelen B, Theeuwes M
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609-10.
    PubMed     Text format    
    
    
    
58. SALFINGER M, Somoskovi A
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609.
    PubMed     Text format    
    
    
    September 2016
59. GUNTHER G, Lange C, Alexandru S, Altet N, et al
    Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:1103-5.
    PubMed     Text format    
    
    
    
60. MASUDA H, Kamada K
    IMAGES IN CLINICAL MEDICINE. Urinary Tract Tuberculosis.
    N Engl J Med. 2016;375:1068.
    PubMed     Text format    
    
    
    
61. ZIGNOL M, Dean AS, Falzon D, van Gemert W, et al
    Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.
    N Engl J Med. 2016;375:1081-9.
    PubMed     Text format    
    
    
    
62. LEGRO RS, Hurtado RM, Kilcoyne A, Roberts DJ, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 28-2016: A 31-Year-Old Woman with Infertility.
    N Engl J Med. 2016;375:1069-77.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: